{"id":"NCT00605280","sponsor":"Pfizer","briefTitle":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","officialTitle":"A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-09","primaryCompletion":"2009-11","completion":"2011-07","firstPosted":"2008-01-31","resultsPosted":"2011-03-30","lastUpdate":"2018-11-16"},"enrollment":317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema Associated With Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Standard of Care","otherNames":[]},{"type":"DRUG","name":"Macugen","otherNames":[]}],"arms":[{"label":"Sham Control","type":"SHAM_COMPARATOR"},{"label":"Macugen","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.","primaryOutcome":{"measure":"Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year","timeFrame":"Baseline, Year 1","effectByArm":[{"arm":"0.3 mg Pegaptanib Sodium","deltaMin":49,"sd":null},{"arm":"Sham","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0047"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":73,"countries":["United States","Australia","Austria","Brazil","Canada","Colombia","Czechia","Denmark","France","Germany","Greece","India","Italy","Netherlands","Portugal","South Africa","Switzerland","United Kingdom"]},"refs":{"pmids":["21896838"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5751013"]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":174},"commonTop":["Conjunctival haemorrhage","Intraocular pressure increased","Macular oedema","Diabetic retinal oedema","Eye pain"]}}